Cellular proliferative fraction of metastatic lymph nodes predicts survival in stage D1 (TxN+M0) prostate cancer

Journal of Urology

Volumn 155, Issue 5, 1996, Pages 1674-1677

  Cher, Michael L ^a   Stephenson, Robert A ^c   James, Brent C ^c   Carroll, Peter R ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE

Author keywords

adenocarcinoma; cell division; nuclear proteins; prostatic neoplasms; tumor markers, biological

Indexed keywords

IODINE 125; MONOCLONAL ANTIBODY KI 67;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; DNA DETERMINATION; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER;

EID: 0029991494     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66162-7     Document Type: Article

References (19)

1. Gasparini, G., Pozza, F. and Harris, A. L.: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J. Natl. Cancer Inst., 85: 1206, 1993.
2. Cher, M. L., Chew, K., Rosenau, W. and Carroll, P. R.: Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate, 26: 87, 1995.
3. Carroll, P. R., Waldman, F. M., Rosenau, W., Cohen, M. B., Vapnek, J. M., Fong, P., Narayan, P. and Mayall, B. H.: Cell proliferation in prostatic adenocarcinoma: in vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression. J. Urol., 149: 403, 1993.
4. Cattoretti, G., Becker, M. H., Key, G., Duchrow, M., Schlüter, C., Galle, J. and Gerdes, J.: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Path., 168: 357, 1992.
5. Botticelli, A. R., Criscuolo, M., Martinelli, A. M., Botticelli, L., Filoni, A. and Migaldi, M.: Proliferating cell nuclear antigen/ cyclin in incidental carcinoma of the prostate. Virchows Arch. Path. Anat. Histopath., 423: 365, 1993.
6. Gallee, M. P. W., Visser-De Jong, E., Ten Kate, F. J. W., Schroeder, F. H. and Van Der Kwast, Th. H.: Monoclonal antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer. J. Urol., 142: 1342, 1989.
7. Harper, M. E., Goddard, L., Wilson, D. W., Matanhelia, S. S., Conn, I. G., Peeling, W. B. and Griffiths, K.: Pathological and clinical associations of Ki-67 defined growth fractions in human prostatic carcinoma. Prostate, 21: 75, 1992.
8. Harper, M. E., Glynne-Jones, E., Goddard, L., Wilson, D. W., Matenhelia, S. S., Conn, I. G., Peeling, W. B. and Griffiths, K: Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters. Prostate, 20: 243, 1992.
9. Lloyd, S. N., Brown, I. L. and Leake, R. E.: Ki-67 antibody immunostaining in benign and malignant human prostatic disease. Int. J. Biol. Markers, 7: 256, 1992.
10. McLoughlin, J., Foster, C. S., Price, P., Williams, G. and Abel, P. D.: Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma. Brit. J. Urol., 72: 92, 1993.
11. Vesalainen, S. L., Lipponen, P. K., Talja, M. T., Alhava, E. M. and Syrjänen, K. J.: Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2M0 prostatic adenocarcinoma. Int. J. Cancer, 58: 303, 1994.
12. Mukamel, E., deKernion, J. B., Hannah, J., Smith, R. B., Skinner, D. G. and Goodwin, W. E.: The incidence and significance of seminal vesicle invasion in patients with adenocarcinoma of the prostate. Cancer, 59: 1535, 1987.
13. McNeal, J. E., Villers, A. A., Redwine, E. A, Freiha, F. S. and Stamey, T. A.: Capsular penetration in prostate cancer. Significance for natural history and treatment. Amer. J. Surg. Path., 14: 240, 1990.
14. Paulson, D. F.: Assessment of anatomic extent and biologic hazard of prostatic adenocarcinoma. Urology, 15: 537, 1980.
15. Sadi, M. V. and Barrack, E. R.: Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy. Cancer, 67: 3065, 1991.
16. Stephenson, R. A., James, B. C., Gay, H., Fair, W. R., Whitmore, W. F. and Melamed, M. R.: Flow cytometry of prostate cancer: relationship of DNA content to survival. Cancer Res., 47:2504, 1987.
17. Hedley, D. W., Friedlander, M. L., Taylor, I. W., Rugg, C. A. and Musgrove, E. A.: Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J. Histochem. Cytochem., 31: 1333, 1983.
18. Bazinet, M., Hamdy, S. M., Bégin, L. R., Stephenson, R. A. and Fair, W. R.: Prognostic significance of antigenic heterogeneity, Gleason grade, and ploidy of lymph node metastases in patients with prostate cancer. Prostate, 20: 311, 1992.
19. Zincke, H., Bergstralh, E. J., Larson-Keller, J. J., Farrow, G. M., Myers, R. P., Lieber, M. M., Barrett, D. M., Rife, C. C. and Gonchoroff, N. J.: Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors. Cancer, suppl., 70: 311, 1992.